Open an account

Revelation Biosciences

REVB · NASDAQ

$3.75+$3.28 (+699.06%)TodayMarket closed ·
Prev close $0.4693

About REVB

Revelation Biosciences, Inc. engages in the development of immunologic-based therapies for the prevention and treatment of disease. The company is headquartered in San Diego, California and currently employs 8 full-time employees. The company went IPO on 2020-10-08. The firm's product candidates are based on the Gemini formulation of phosphorylated hexaacyl disaccharide (PHAD). The firm has multiple ongoing programs to evaluate Gemini, including GEM-AKI as a prevention of acute kidney injury (AKI), GEM-CKD as a treatment for chronic kidney disease (CKD), and GEM-PSI as a prevention of post-surgical infection (PSI). The Gemini-AKI program is being developed as a potential therapy for the prevention of AKI due to external stress or insult, such as surgical procedure and chemotherapy toxicity. GEM-PSI is being developed as a potential therapy for the prevention or treatment of healthcare-associated bacterial infections, including post-surgical infection, post-burn infection, urinary tract infection, sepsis, and antibiotic-resistant infection.

Employees
8
Headquarters
San Diego, California
Listed
Oct 8, 2020
Sector
Health Care
Industry
Biotechnology
Website
revbiosciences.com

REVB key statistics

Market cap
13.09M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
82.68K
Volume
158.86K
Open price
$3.30
High today
$4.06
Low today
$3.29
52 Week high
$5.80
52 Week low
$0.44

Revelation Biosciences (REVB) at a glance

Revelation Biosciences (REVB) last traded at $3.75, with a market cap of 13.09M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.29 and $4.06. The current price is 13.9% above the day's low and 7.6% below its high.

Volume so far is 158.86K shares, above the average of 82.68K shares a day.

Over the past year Revelation Biosciences has ranged from $0.44 to $5.80, and now sits 62% of the way up that range.

Revelation Biosciences met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.87 per share against an estimate of -$0.8466.

REVB earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 50.4% on average.

  1. Q3 FY24: reported -$161.28 per share against an estimate of -$556.19
  2. Q4 FY24: reported -$59.76 per share against an estimate of -$66.59
  3. Q1 FY25: reported -$25.32 per share against an estimate of -$84.21
  4. Q2 FY25: reported -$28.04 per share against an estimate of -$18.18
  5. Q3 FY25: reported -$7.08 per share against an estimate of -$5.45
  6. Q4 FY25: reported -$23.95 per share against an estimate of -$3.73
  7. Q1 FY26: reported -$2.71 per share against an estimate of -$1.17
  8. Q2 FY26: reported -$0.87 per share against an estimate of -$0.8466

REVB news

  • Press releaseBusiness Wire

    Revelation Biosciences Announces 1-for-7 Reverse Stock Split Effective October 20, 2026

  • Press releaseBusiness Wire

    Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study

  • Press releaseACCESS Newswire

    Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders

  • Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation

  • Watching Revelation Biosciences; Zacks Small-Cap Research Gives Stock $22.50 Price Valuation

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • Watching Revelation Bios; Zacks Small-Cap Research Gives Stock $21.45 Price Valuation

Similar companies

Companies in the same industry as Revelation Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.